Geraldine Ferron-Brady

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Cross Sectional

Acute Lymphoblastic Leukemia

Multiple Myeloma

Top Venues

Clinical and translational science

CPT: pharmacometrics & systems pharmacology

Clinical cancer research : an official journal of the American Association for Cancer Research

JNCI cancer spectrum

This page only lists publications with an associated author ORCID identifier.

Publications

Georgios Vlasakakis, Michael T McCabe, Yu Liu Ho, Geraldine Ferron-Brady, Paul Martin, Darren J Bentley, Catherine Ellis, Mary Antonysamy, Sandra A G Visser
Momelotinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (8) (2024)
Yu Liu Ho, Peter D Gorycki, Geraldine Ferron-Brady, Paul Martin, Georgios Vlasakakis
Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters. Clinical and translational science 17 (4) (2024)
Yu Liu Ho, Peter D Gorycki, Geraldine Ferron-Brady, Paul Martin, Georgios Vlasakakis
Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters. Clinical and translational science 17 (4) (2024)
Yu Liu Ho, Peter D Gorycki, Geraldine Ferron-Brady, Paul Martin, Georgios Vlasakakis
Clinical assessment of momelotinib drug-drug interactions via CYP3A metabolism and transporters. Clinical and translational science 17 (4) (2024)
Georgios Vlasakakis, Michael T McCabe, Yu Liu Ho, Geraldine Ferron-Brady, Paul Martin, Darren J Bentley, Catherine Ellis, Mary Antonysamy, Sandra A G Visser
Momelotinib: Mechanism of action, clinical, and translational science. Clinical and translational science 17 (8) (2024)
Jon Collins, Martijn van Noort, Chetan Rathi, Teun M Post, Herbert Struemper, Roxanne C Jewell, Geraldine Ferron-Brady
Longitudinal Efficacy and Safety Modeling and Simulation Framework to Aid Dose Selection of Belantamab Mafodotin for Patients with Multiple Myeloma. CPT: pharmacometrics & systems pharmacology (2023)
Richard Hooijmaijers, Ridhi Parasrampuria, Eleonora Marostica, Geraldine Ferron-Brady, Teun M Post, Sandra A G Visser
Building an adaptive dose simulation framework to aid dose and schedule selection. CPT: pharmacometrics & systems pharmacology (2023)
Mark A Dawson, Gautam Borthakur, Brian James Patrick Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T Vogl, Daniel A Pollyea, Faith E Davies, Gareth J Morgan, Jacob Lowell Glass, Manali Kamdar, Maria-Victoria Mateos-Manteca, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O Karpinich, Michael T McCabe, Shawn W Foley, Thierry Horner, Arindam Dhar, Brandon E Kremer, Michael J Dickinson
A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Sarina A Piha-Paul, Christine L Hann, Christopher A French, Sophie Cousin, Irene Braña, Phillippe A Cassier, Victor Moreno, Johann S de Bono, Sara Duckworth Harward, Geraldine Ferron-Brady, Olena Barbash, Anastasia Wyce, Yuehui Wu, Thierry Horner, Meg Annan, Nigel J Parr, Rabinder K Prinjha, Christopher L Carpenter, John Hilton, David S Hong, Naomi B Haas, Mark C Markowski, Arindam Dhar, Peter J O'Dwyer, Geoffrey I Shapiro
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI cancer spectrum 4 (2) (2019)